Compare
Olema Pharmaceuticals, Inc. vs Rigel Pharmaceuticals Inc vs Rapport Therapeutics, Inc. vs Ardelyx, Inc.
| Latest fiscal year | Olema Pharmaceuticals, Inc. OLMA | Rigel Pharmaceuticals Inc RIGLRevenue covers only part of its income (partial revenue) | Rapport Therapeutics, Inc. RAPP | Ardelyx, Inc. ARDX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $407.32M |
| Revenue growth (YoY) | n/a | n/a | n/a | +22.1% |
| Gross margin | n/a | n/a | n/a | 90.3% (computed) |
| Operating margin | n/a | n/a | n/a | -10.1% |
| Net margin | n/a | n/a | n/a | -15.1% |
| Net income | -$162.45M | $367.02M | -$111.48M | -$61.60M |
| EPS (Diluted) | -$1.87 | $19.48 | -$2.86 | -$0.26 |
| Operating cash flow | -$146.72M | $75.66M | -$87.47M | -$42.48M |
| Free cash flow | n/a | n/a | -$88.09M | -$43.98M |
| Cash & equivalents | $48.30M | $40.58M | $52.65M | $68.00M |
| Total assets | $533.43M | $513.59M | $512.43M | $501.60M |
| Total liabilities | $54.87M | $122.11M | $27.78M | $334.65M |
| Shareholders' equity | $478.56M | $391.48M | $484.65M | $166.95M |
| Return on year-end equity | -33.9% | 93.8% | -23.0% | -36.9% |
| Shares outstanding | 81.38M | 18.31M | 47.77M | 244.35M |
Revenue, most recent five fiscal years
| Fiscal year | Olema Pharmaceuticals, Inc. | Rigel Pharmaceuticals Inc | Rapport Therapeutics, Inc. | Ardelyx, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $407.32M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $333.62M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $124.46M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $52.16M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $10.10M Ended 2021-12-31 |